---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005023"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:56:14.321065+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PAVmed closes $30M Series D Preferred and $15M Note, retires all convertible securities

## Summary
- Gross proceeds $30M from Series D Preferred; warrants exercisable for additional $30M upon positive Medicare LCD for EsoGuard.
- New $15M senior secured note with 15% interest, matures Feb 2029, to existing investor.
- Used $22.3M cash + $15M note to redeem all Series C Preferred and retire convertible debt; net cash $7.7M.
- Series D convertible at $6.50/share; special meeting by April 30, 2026 to seek stockholder approval for conversion.
- Eliminates legacy convertible overhang; PAVmed holds 31M shares of Lucid Diagnostics (Nasdaq: LUCD).

## SEC filing metadata
- accession: 0001493152-26-005023
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/0001493152-26-005023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005023
- JSON: https://secwatch.observer/filing/0001493152-26-005023.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005023.txt

## Key facts
- Material Agreements
  PAVmed Inc. amended Amended and Restated 2022 Note (the "2026 Note") with the Holder valued at $15 million principal amount (effective 2026-02-03).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: the Holder
  - Value: $15 million principal amount
  - Effective: 2026-02-03
  source text: Concurrently with the Offering, the Company redeemed all 16,962 shares of Series C Preferred Stock outstanding and refinanced all $8,414,890 in principal and interest of its Senior Secured Convertible Note issued in September (the “ 2022 Note ”), in consideration of a cash payment to the holder thereof (the “ Holder ”) of approximately $22,346,241 (which was made using proceeds from the sale of the Series D Preferred Stock), and the issuance to the Holder of an amended and restated 2022 Note (the “ 2026 Note ”) with a principal amount of $15 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/0001493152-26-005023-index.htm
- Material Agreements
  PAVmed Inc. entered into Subscription Agreements with certain accredited investors valued at $30 million aggregate purchase price (effective 2026-02-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $30 million aggregate purchase price
  - Effective: 2026-02-03
  source text: On February 3, 2026, PAVmed Inc. (the “ Company ”) entered into subscription agreements (the “ Subscription Agreements ”) with certain accredited investors (the “ Investors ”) and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D Convertible Preferred Stock, par value $0.001 per share (the “ Series D Preferred Stock ”), and (ii) warrants (the “ Warrant ”) to purchase an additional 30,000 shares of Series D Preferred Stock, with each investor receiving 100 shares of Series D Preferred Stock and a warrant to purchase 100 shares of Series D Preferred Stock for each $100,000 of its investment (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/0001493152-26-005023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.